Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Consensus PT from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $56.57.

Several equities research analysts have recently weighed in on the company. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target on the stock. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank increased their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $35.54 on Monday. The business’s 50 day moving average price is $33.89 and its 200-day moving average price is $42.73. Agios Pharmaceuticals has a fifty-two week low of $27.14 and a fifty-two week high of $62.58. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 3.13 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Sell-side analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. Creative Planning boosted its position in Agios Pharmaceuticals by 35.8% during the 3rd quarter. Creative Planning now owns 15,640 shares of the biopharmaceutical company’s stock valued at $695,000 after acquiring an additional 4,120 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Agios Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,942 shares of the biopharmaceutical company’s stock valued at $486,000 after acquiring an additional 4,272 shares in the last quarter. Oak Ridge Investments LLC boosted its position in Agios Pharmaceuticals by 14.6% during the 3rd quarter. Oak Ridge Investments LLC now owns 40,378 shares of the biopharmaceutical company’s stock valued at $1,794,000 after acquiring an additional 5,142 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its position in Agios Pharmaceuticals by 19.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 39,090 shares of the biopharmaceutical company’s stock valued at $1,737,000 after acquiring an additional 6,320 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.